Abstract
Addiction is a chronic-relapsing brain disorder characterized by cognitive, behavioral, and physiological symptoms including compulsion to take the drug, loss of control over use, and persistent consumption despite substance-related problems. Individual susceptibility is influenced by genetic, psychological, and environmental factors; age of first exposure; substance characteristics; and pattern of use. Substances of abuse act on several brain’s systems leading to persistent changes, which can trigger relapse even after prolonged abstinence. Addiction is a major public health concern. About 35.6 million people worldwide suffer from substance use disorders (SUDs), whose prevalence is expected to continue to grow. SUDs are associated with psychiatric conditions, adverse health consequences, and social disadvantage. Despite their high prevalence and their impact in terms of mortality, morbidity, and societal costs, health-care providers report inadequate preparedness in recognizing and supporting patients with SUDs. Awareness of risk factors, knowledge of the underlying neurobiological mechanisms and identification of early signs make it possible to implement prevention and treatment strategies for SUDs. Therefore, this chapter aims to discuss the identification, management, and treatment of substance-related disorders, providing health-care professionals with fundamental tools to face one of the most challenging public health threats to our society.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
Campeny E, López-Pelayo H, Nutt D, et al. The blind men and the elephant: systematic review of systematic reviews of cannabis use related health harms. Eur Neuropsychopharmacol. 2020;33:1–35. https://doi.org/10.1016/j.euroneuro.2020.02.003.
Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394(10200):781–92. https://doi.org/10.1016/S0140-6736(19)31775-1.
Center for Health Information and Analysis. Access to substance use disorder treatment in Massachusetts. Boston: Center for Health Information and Analysis; 2015.
Daley D. Family and social aspects of substance use disorders and treatment. J Food Drug Anal. 2013;21(4):S73–6.
Donroe JH, Tetrault JM. Substance use, intoxication, and withdrawal in the critical care setting. Crit Care Clin. 2017;33(3):543–58. https://doi.org/10.1016/j.ccc.2017.03.003.
European Monitoring Centre for Drugs and Drug Addiction. European drug report 2020: trends and developments. Luxembourg: Publications Office of the European Union; 2020.
Khademi H, Kamangar F, Brennan P, Malekzadeh R. Opioid therapy and its side effects: a review. Arch Iran Med. 2016;19(12):870–6.
Klein WJ. Pharmacotherapy for substance use disorders. Med Clin N Am. 2016;100(4):891–910.
Kuntsche E, Kuntsche S, Thrul J, Gmel G. Binge drinking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):976–1017. https://doi.org/10.1080/08870446.2017.1325889.
Lappin JM, Sara GE. Psychostimulant use and the brain. Addiction. 2019;114(11):2065–77. https://doi.org/10.1111/add.14708.
Morgan CJ, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 2012;107(1):27–38. https://doi.org/10.1111/j.1360-0443.2011.03576.x.
Ouzir M, Errami M. Etiological theories of addiction: a comprehensive update on neurobiological, genetic and behavioural vulnerability. Pharmacol Biochem Behav. 2016;148:59–68. https://doi.org/10.1016/j.pbb.2016.06.005.
Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668–84. https://doi.org/10.1016/S0140-6736(19)32231-7.
Tenegra JC, Leebold B. Substance abuse screening and treatment. Prim Care. 2016;43(2):217–27. https://doi.org/10.1016/j.pop.2016.01.008.
Volkow ND. Personalizing the treatment of substance use disorders. Am J Psychiatry. 2020;177(2):113–6. https://doi.org/10.1176/appi.ajp.2019.19121284.
Volkow ND, Boyle M. Neuroscience of addiction: relevance to prevention and treatment. Am J Psychiatry. 2018;175(8):729–40. https://doi.org/10.1176/appi.ajp.2018.17101174.
Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016a;374(4):363–71. https://doi.org/10.1056/NEJMra1511480.
Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016b;73(3):292–7. https://doi.org/10.1001/jamapsychiatry.2015.3278.
World Drug Report. World Drug Report. 2020. (United Nations publication, Sales No. E.20.XI.6).
World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Martini, F., Fregna, L., Bosia, M., Perrozzi, G., Cavallaro, R. (2022). Substance-Related Disorders. In: Cavallaro, R., Colombo, C. (eds) Fundamentals of Psychiatry for Health Care Professionals . Springer, Cham. https://doi.org/10.1007/978-3-031-07715-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-031-07715-9_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-07714-2
Online ISBN: 978-3-031-07715-9
eBook Packages: MedicineMedicine (R0)